✦ LIBER ✦

A26. A phase I/II pilot trial of low-dose, sustained-release GTN for prostate cancer patients with recurrence after primary therapy

✍ Scribed by D.R. Siemens; J. Heaton; M. Adams; C. Graham

Book ID: 116790387
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 43 KB
Volume: 17
Category: Article
ISSN: 1089-8603
DOI: 10.1016/j.niox.2007.09.031

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I-II prospective dose-escalating t

Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy

✍ Peter E. Clark; M. Craig Hall; Lester S. Borden Jr; Antonius A. Miller; Jennifer 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 107 KB

Combined low-dose flutamide plus finaste

Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up

✍ Lionel L. Bañez; Gary W. Blake; David G. McLeod; E. David Crawford; Judd W. Moul 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB

Chemotherapy in patients with prostate s

Chemotherapy in patients with prostate specific antigen–only disease after primary therapy for prostate carcinoma : A Phase II trial of oral estramustine and oral etoposide

✍ Hidayatullah G. Munshi; Kenneth J. Pienta; David C. Smith 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

## BACKGROUND. A Phase II study was initiated to evaluate the effectiveness of an oral regimen of etoposide and estramustine in patients with early recurrent prostate carcinoma. ## METHODS. Patients with early recurrent prostate carcinoma as indicated by an increasing prostate specific antigen